The effects of Teneligliptin on vascular inflammatory markers in post-PCI (Percutaneous Coronary Intervention) patients.
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2018
Price : $35 *
At a glance
- Drugs Teneligliptin (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 15 Nov 2018 Status changed from recruiting to completed.
- 04 May 2017 New trial record